Safety and efficacy of tenofovir in chronic hepatitis B-related decompensated cirrhosis

Table 5 Changes of creatinine clearance (eGFR) during tenofovir disoproxil fumarate therapy for 12 mo

	All (n = 174)	Mean eGFR (CKD-EPI equation)		P value
		Compensated LC (n = 117)	Decompensated LC (n = 57)
Baseline	95.2 ± 17.8	95.4 ± 14.8	94.8 ± 23.0	0.880
Week 12	91.1 ± 16.2	93.2 ± 13.0	86.6 ± 21.1	0.205
Week 24	91.1 ± 17.5	92.2 ± 14.2	89.2 ± 22.0	0.895
Week 36	90.6 ± 16.6	91.1 ± 14.4	89.7 ± 20.3	0.943
Week 48	90.7 ± 18.4	91.6 ± 14.9	88.9 ± 23.8	0.959

LC: Liver cirrhosis.